OSLO, Norway, Dec. 1, 2022 /PRNewswire/ — An Extraordinary General Meeting (the “EGM”) of Nordic Nanovector ASA (the “Company”) (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway.
The matters under item 3, the proposed transaction with APIM Therapeutics AS, did not obtain sufficient majority of votes and was thus voted down. Due to the results under item 3, the EGM did not vote for the matters under item 4, 5, 6 and 7. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com.
For further information, please contact:
IR enquiries
Malene Brondberg, interim CEO and CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
The following files are available for download:
SOURCE Nordic Nanovector